Related Experiment Video

Updated: May 6, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

6.5K

A retrospective analysis of two different sequences of therapy lines for advanced kidney cancer

Chiara Paglino1, Giuseppe Procopio, Roberto Sabbatini

  • 1Medical Oncology, San Matteo University Hospital Foundation, Piazzale C. Golgi, 19, 27100 Pavia, Italy. c.porta@smatteo.pv.it.

Anticancer Research
|November 14, 2013
PubMed
Abstract

Insights

The sequence of targeted agents, including sorafenib and sunitinib (mammalian target of rapamycin inhibitors), does not significantly impact progression-free survival in advanced kidney cancer patients. Both sequential approaches demonstrated similar clinical benefits.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • The optimal sequencing of targeted therapies for advanced kidney cancer remains undetermined.
  • Investigating sequential administration of sorafenib and mammalian target of rapamycin inhibitors (mTORi) with sunitinib is crucial for treatment optimization.

Purpose of the Study:

  • To compare the clinical efficacy of two distinct sequential treatment strategies in advanced kidney cancer.
  • To evaluate the progression-free survival (PFS) associated with sorafenib-mTORi-sunitinib versus sunitinib-mTORi-sorafenib sequences.

Main Methods:

  • Retrospective analysis of outcomes in 40 advanced kidney cancer patients.
  • Comparison of two treatment sequences: sorafenib-mTORi-sunitinib (n=26) and sunitinib-mTORi-sorafenib (n=14).

Main Results:

  • Overall median PFS was comparable between the sorafenib-mTORi-sunitinib (21.9 months) and sunitinib-mTORi-sorafenib (22.8 months) groups (p=0.928).
  • First-line PFS was 11.7 months for sorafenib-mTORi-sunitinib and 14.4 months for sunitinib-mTORi-sorafenib.
  • Subsequent-line PFS showed variations but did not lead to significant overall differences.

Conclusions:

  • No significant difference in clinical benefit was observed between the two evaluated sequential treatment modalities for advanced kidney cancer.
  • The findings suggest flexibility in sequencing sorafenib and sunitinib in combination with mTOR inhibitors.
Keywords:
Kidney cancerdrug sequenceeverolimussorafenibsunitinibtemisrolimus

More Related Videos

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers12:22

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

33.1K
A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

13.0K

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K
Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
870
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.1K
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
726
Kidney Transplant II: Surgical Procedure01:26

Kidney Transplant II: Surgical Procedure

Preoperative ManagementThe primary goals of preoperative management in kidney transplantation are to optimize the patient’s metabolic state and prepare them for surgery through diet adjustments, necessary dialysis, and tailored medical treatment. This phase also involves comprehensive infection screening and patient education about the surgical procedure and postoperative care to improve outcomes and adherence.Medical ManagementA comprehensive evaluation is required for both the living...
955